GlassScriptPhysician profile
Paul S Jensen
NPI 1891792370
$2,998.86
in general payments reported to CMS, 2019-2025
11 companies · $80.74 in 2025
The $80.74 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2021: $22.22 · 2022: $163 · 2023: $15.65 · 2024: $2,282 · 2025: $80.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,473 · Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,473.19 |
| Food and Beverage | $905.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,272.05 | 2019-2025 | |
| Oyster Point Pharma, INC. | $171.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.87 | 2019 | |
| Mallinckrodt Enterprises LLC | $124.96 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $108.28 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $100.20 | 2024 | Xdemvy |
| Lombart Brothers, INC. | $39.76 | 2019 | |
| Lkc Technologies, INC. | $24.90 | 2024 | |
| Bausch & Lomb Americas INC. | $13.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $12.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.